Compare · ORKA vs VNRX
ORKA vs VNRX
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.59B, about 422.0x VNRX ($13.2M).
- Over the past year, ORKA is up 538.2% and VNRX is down 92.2% - ORKA leads by 630.4 points.
- ORKA has been more active in the news (5 items in the past 4 weeks vs 2 for VNRX).
- ORKA has more recent analyst coverage (11 ratings vs 4 for VNRX).
PerformanceORKA+538.24%VNRX-92.18%
2025-07-18+0.00%2026-07-17
- Company
- Oruka Therapeutics Inc.
- VolitionRX Limited
- Price
- $92.80+11.61%
- $1.11-5.93%
- Market cap
- $5.59B
- $13.2M
- 1M return
- +37.12%
- -21.28%
- 1Y return
- +538.24%
- -92.18%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 5
- 2
- Recent ratings
- 11
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)
Latest VNRX
- SEC Form S-3 filed by VolitionRX Limited
- VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRx Announces Collaboration with Sysmex
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Announces Pricing of $4.6 Million Public Offering
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
- SEC Form DEF 14A filed by VolitionRX Limited
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets